MiNK Therapeutics (MiNK Therapeutics) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MiNK Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-2.54 Mil. MiNK Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, MiNK Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, MiNK Therapeutics's current FCF Yield % is -40.54%.

The historical rank and industry rank for MiNK Therapeutics's FCF Margin % or its related term are showing as below:

During the past 5 years, the highest FCF Margin % of MiNK Therapeutics was -2227.54%. The lowest was -2227.54%. And the median was -2227.54%.

INKT's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.09
* Ranked among companies with meaningful FCF Margin % only.

MiNK Therapeutics FCF Margin % Historical Data

The historical data trend for MiNK Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics FCF Margin % Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-2,227.54

MiNK Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of MiNK Therapeutics's FCF Margin %

For the Biotechnology subindustry, MiNK Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's FCF Margin % falls into.

MiNK Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MiNK Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.837	/	0
	=	%

MiNK Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.542	/	0
	=	%

MiNK Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics (MiNK Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010